These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22828248)

  • 1. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
    Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
    Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
    Kim GH; Levy A; Compoginis G
    J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
    Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
    West ES; Williams VL; Morelli JG
    Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
    Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
    J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
    [No Abstract]   [Full Text] [Related]  

  • 11. Panniculitis in patients treated with BRAF inhibitors: a case series.
    Choy B; Chou S; Anforth R; Fernández-Peñas P
    Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib-induced panniculitis.
    Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
    Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
    [No Abstract]   [Full Text] [Related]  

  • 14. Case of vemurafenib-induced Sweet's syndrome.
    Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
    J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
    Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
    Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
    Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
    Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
    [No Abstract]   [Full Text] [Related]  

  • 17. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
    Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
    Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
    Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
    Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.